ObjectiveTo determine whether COVID-19 infection is an independent risk factor for the presentation of major adverse cardiovascular events (MACE) in the short and medium term in a series of patients with acute coronary syndrome (ACS) who received percutaneous coronary intervention.Methods115 patients were recruited, from March 1, 2020, to January 31, 2021, patients who presented ACS accepted in the international ASISSSTE infarction program and underwent diagnostic and/or therapeutic coronary angiography, with or without COVID-19 infection.ResultsTabled 1Complications and major adverse cardiovascular events in the group of studyVariableMild PneumoniaSevere PneumoniaPCardiogenic shock1 (12.5%)5 (62.5%)0.039Tachyarrhythmia / Bradyarrhythmia1 (12.5%)0 (0.0%)0.302Death1 (12.5%)5 (62.5%)0.039CVE0 (0.0%)1 (12.5%)0.302Acute kidney injury0 (0.0%)5 (62.5%)0.007days of hospital stay4.38 ± 2.929.25 ± 6.220.065 Open table in a new tab ConclusionsAccording to the experience of our center, in those patients with ACS and pneumonia due to COVID, an increased risk of presenting cardiogenic shock and acute kidney injury was documented, which resulted in an increased risk of major cardiovascular events manifested by increased mortality.DisclosuresAbdon Avila Chavez: Nothing to disclose. J. Alfredo Merino: Nothing to disclose. Carlos Madrigal: Nothing to disclose. Hiram Vela Vizcano: Nothing to disclose. ObjectiveTo determine whether COVID-19 infection is an independent risk factor for the presentation of major adverse cardiovascular events (MACE) in the short and medium term in a series of patients with acute coronary syndrome (ACS) who received percutaneous coronary intervention. To determine whether COVID-19 infection is an independent risk factor for the presentation of major adverse cardiovascular events (MACE) in the short and medium term in a series of patients with acute coronary syndrome (ACS) who received percutaneous coronary intervention. Methods115 patients were recruited, from March 1, 2020, to January 31, 2021, patients who presented ACS accepted in the international ASISSSTE infarction program and underwent diagnostic and/or therapeutic coronary angiography, with or without COVID-19 infection. 115 patients were recruited, from March 1, 2020, to January 31, 2021, patients who presented ACS accepted in the international ASISSSTE infarction program and underwent diagnostic and/or therapeutic coronary angiography, with or without COVID-19 infection. ResultsTabled 1Complications and major adverse cardiovascular events in the group of studyVariableMild PneumoniaSevere PneumoniaPCardiogenic shock1 (12.5%)5 (62.5%)0.039Tachyarrhythmia / Bradyarrhythmia1 (12.5%)0 (0.0%)0.302Death1 (12.5%)5 (62.5%)0.039CVE0 (0.0%)1 (12.5%)0.302Acute kidney injury0 (0.0%)5 (62.5%)0.007days of hospital stay4.38 ± 2.929.25 ± 6.220.065 Open table in a new tab ConclusionsAccording to the experience of our center, in those patients with ACS and pneumonia due to COVID, an increased risk of presenting cardiogenic shock and acute kidney injury was documented, which resulted in an increased risk of major cardiovascular events manifested by increased mortality. According to the experience of our center, in those patients with ACS and pneumonia due to COVID, an increased risk of presenting cardiogenic shock and acute kidney injury was documented, which resulted in an increased risk of major cardiovascular events manifested by increased mortality.